InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-45.3%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Scherle Peggy, Directeur Scientifique. Director active across 1 company, notably Prelude Therapeutics Inc. Cumulatively, 8 disclosures have been published. History available since 7 May 2021. The latest transaction was disclosed on 26 August 2021 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations8 total
1,700 shares@ US$1.432.7% of flowCommon StockSEC:0001209191-21-053867
1,700 shares@ US$1.430.0006% mcap2.7% of flowCommon StockSEC:0001209191-21-053867:0
558 shares@ US$1.890.0003% mcap1.2% of flowCommon StockSEC:0001209191-21-051885:0
558 shares@ US$1.891.2% of flowCommon StockSEC:0001209191-21-051885
20,000 shares@ US$1.4331.0% of flowCommon StockSEC:0001209191-21-048688
20,000 shares@ US$1.430.0068% mcap31.0% of flowCommon StockSEC:0001209191-21-048688:0
10,000 shares@ US$1.4315.2% of flowCommon StockSEC:0001209191-21-031847
10,000 shares@ US$1.430.0033% mcap15.2% of flowCommon StockSEC:0001209191-21-031847:0
8 of 8 declarations
About Scherle Peggy
Peggy Scherle is the Chief Scientific Officer at Prelude Therapeutics Inc, a biopharmaceutical company. She is responsible for leading research and development initiatives aimed at innovating in the field of medical treatments.
